Recent news

Check out the latest news on the field of psychedelics.

Irene de Caso, 'Psychedelics and Mental Health' author, will work with Beckley Foundation

By Gabriel García on January 26, 2023

The Beckley Foundation, a leading entity in the field of psychedelic research, has recently announced the incorporation of researcher Irene de Caso as part of the team of Amanda Feilding, founding director of the foundation. This news is especially relevant in the field of mental health, as Irene de Caso is the author of the book “Psychedelics and Mental Health” which is part of the Psychonaut’s Guides collection.

More information

Virtual Reality on psychedelic therapies?

By Gabriel García on January 19, 2023

Virtual reality (VR) is an emerging technology that is increasingly being used in a variety of fields, from entertainment to, more recently, medicine. Within the medical field, in recent years, there has been a growing interest in using VR to recreate experiences with psychedelics, with the aim of investigating their therapeutic effects and improving the understanding of how these substances affect the brain and human behavior as a substitute for the original substances.

More information

Meet: Rick Doblin

By Gabriel García on December 21, 2022

Original text source: Take a look at our social networks to keep updated: ⇦ Back Born in 1953, Doblin grew up in a conservative Jewish family in the Chicago suburbs. He is the first of four children of pediatrician Morton Doblin and schoolteacher Arline Doblin. He has three younger siblings, Bruce, Sharon and Stuart Doblin.

More information

Germany funds psilocybin study with €2.6m

By Gabriel García on December 14, 2022

Germany’s Federal Ministry of Education and Research (BMBF) has granted €2.6m to a study investigating the potential effectiveness of psilocybin as an antidepressant treatment for people who cannot tolerate conventional treatments. The “Efficacy and safety of Psilocybin in treatment-resistant major depression” (EpisoDE) study was launched by the Central Institute for Mental Health (CIMH) Mannheim in 2021. The purpose of this study is to determine whether psilocybin is an effective treatment for people with severe depression.

More information